The incidence and prevalence of metabolic and musculoskeletal diseases are increasing.
Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance, inflammation …

Previous guidelines for the treatment of people with type 2 diabetes mellitus (T2D) have
relied heavily upon rigid algorithms for the sequential addition of pharmacotherapies to …

As obesity rates increase, so too do the risks of type 2 diabetes, cardiovascular disease, and
numerous other detrimental conditions. The prevalence of obesity in US adults more than …

Diabetes is a growing global health concern, as is obesity. Diabetes and obesity are
intrinsically linked: obesity increases the risk of diabetes and also contributes to disease …

OBJECTIVE This multicenter, double-blind, treat-to-target, phase 3 trial evaluated the
efficacy and safety of fast-acting insulin aspart (faster aspart) versus insulin aspart (IAsp) in …

Obesity is a complex worldwide disease, characterized by an abnormal or excessive fat
accumulation. The onset of this pathology is generally linked to a complex network of …

OBJECTIVE Moderate weight gain is usual after starting insulin therapy. The identification
and quantification of factors associated with weight gain may help target strategies for …

The overall impact of glucose lowering on vascular complications and major clinical
outcomes, including mortality, in type 2 diabetes is still an open issue. While intensive …

Abstract Aims/Introduction Canagliflozin is a sodium–glucose cotransporter 2 inhibitor under
development for the treatment of type 2 diabetes. Our aim was to examine its efficacy and …

Basal insulin therapy is a critical part of effective type 2 diabetes (T2D) management for
many patients, yet its initiation and titration are often delayed or avoided. Aversion to basal …